Mircette® is a low-dose oral contraceptive for patients who prefer a monthly period.


Cycle control with 10 mcg of estrogen on days 24 through 28 Low incidence of breakthrough bleeding (3.5%) and spotting (8.9%)¹

Each package contains 21 tablets of 0.15 mg desogestrel and 20 mcg ethinyl estradiol (EE), 2 placebo tablets, and 5 tablets of 10 mcg EE.

Mircette^® tablets are indicated for the prevention of pregnancy.

Serious as well as minor side effects can occur with oral contraceptives. Serious risks include myocardial infarction, thromboembolism, stroke, hepatic neoplasia and gallbladder disease. Cigarette smoking increases the risk of serious cardiovascular side effects; women who take oral contraceptives are strongly advised not to smoke. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity and diabetes. Oral contraceptives do not protect against HIV infection (AIDS) and other sexually transmitted infections.

1. The Mircette^® Study Group. An open-label, multicenter, noncomparative safety and efficacy study of Mircette^®, a low-dose
estrogen-progestin oral contraceptive. Am J Obstet Gynecol. 1998;179:S2-S8.

© 2007 Duramed Pharmaceuticals, Inc. All rights reserved.

Mircette^® and Duramed^® are registered trademarks of Duramed Pharmaceuticals, Inc.
Duramed is a subsidiary of Barr Pharmaceuticals, Inc.
The site is intended for residents of the United States only.